Research Papers:

Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2/STAT3 pathway

Weigang Xiu, Juan Ma, Ting Lei, Man Zhang _ and Shangyan Zhou

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:63204-63214. https://doi.org/10.18632/oncotarget.11434

Metrics: PDF 2485 views  |   HTML 2975 views  |   ?  


Weigang Xiu1,2, Juan Ma1,2, Ting Lei1,2, Man Zhang1,2, Shangyan Zhou1,2

1Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

2Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Correspondence to:

Man Zhang, email: [email protected]

Keywords: bladder cancer, dendritic cell, anti-tumor immunity, immunotherapy, Janus kinase 2/signal transducer and activator of transcription 3 pathway

Received: April 20, 2016     Accepted: August 11, 2016     Published: August 20, 2016


Function of dendritic cells (DCs) is impaired by some cancer cells. However, the effect of bladder cancer cell (BCC) on phenotype and function of DCs remains unclear. In this study, healthy human peripheral blood mononuclear cells (PBMCs) derived DCs were co-cultured with BCC pumc-91 and adriamycin-resistant pumc-91/ADM. The expression of DC markers and costimulatory molecules decreased after co-culture. Co-cultured DCs rapidly underwent apoptosis, and had a declined capability to produce IL-8 and RANTES. Furthermore, co-cultured DCs showed impaired allogeneic T cell proliferation and T cell-derived cytokine secretion. Finally, AG490, a Jak2/STAT3 inhibitor, restored the expression of DC markers and costimulatory molecules. Of note, compared with control DCs, DCs co-cultured with pumc-91 produced more IP-10; DCs co-cultured with pumc-91/ADM secreted more MIG. Taken together, these results suggest BCC may inhibit maturation and function of DCs involving of Jak2/STAT3 pathway, and there may be different mechanisms by which adriamycin-resistant BCC restrains DC function in antitumor immune response.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11434